Want to see IN:KREBSBIO full AI Analyst Report?
Top Page
Krebs Biochemicals & Industries Ltd.
(KREBSBIO)
Select Model
Select Model
Rating:47Neutral
Price Target:
₹59.00
▼(-16.90% Downside)
Action:Upgraded
Date:09/10/26
The score is held down primarily by very weak financial performance (recurring losses, negative equity, and persistent negative free cash flow). Technical indicators are moderately supportive (price above key moving averages with mildly positive momentum), but valuation remains challenged due to negative earnings and no dividend yield data.
Positive Factors
Gross Margin Recovery
Gross margin turning positive in 2025–2026 indicates product-level economics improved from the earlier negative-margin period. However, the pack says this has not produced sustainable profitability, so the benefit is best viewed as a potential operational foothold rather than an established earnings advantage.
Negative Factors
Negative Equity and Leverage
Persistently negative equity and heavy debt relative to the asset base materially weaken balance-sheet resilience. This combination raises solvency and refinancing risk, while limiting the company’s ability to absorb operating setbacks or fund future investment without additional financial pressure.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross Margin Recovery
Gross margin turning positive in 2025–2026 indicates product-level economics improved from the earlier negative-margin period. However, the pack says this has not produced sustainable profitability, so the benefit is best viewed as a potential operational foothold rather than an established earnings advantage.
Read all positive factors
Krebs Biochemicals & Industries Ltd. (KREBSBIO) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.23B
Dividend YieldN/A
Average Volume (3M)2.63K
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue Growth-29.72%
EPS Growth47.98%
CountryIN
Employees142
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-6.54
Shares Outstanding21,560,587
10 Day Avg. Volume6,521
30 Day Avg. Volume2,629
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-0.53
Price to Sales (P/S)3.61
P/FCF Ratio-7.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Krebs Biochemicals & Industries Ltd. Business Overview & Revenue Model
Company Description
Established in 1991 and headquartered in Hyderabad, India, Krebs Biochemicals & Industries Limited primarily focuses on the production and distribution of active pharmaceutical ingredients (APIs) across India. The company also innovates by develop...
How the Company Makes Money
KREBSBIO primarily makes money by manufacturing chemical products and selling them to customers, generating revenue from product sales (typically recognized upon dispatch/delivery under customer contracts). Its earnings are driven by (a) sales vol...
Krebs Biochemicals & Industries Ltd. Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 252.34M | 237.32M | 433.12M | 504.21M | 521.34M | 597.03M |
| Gross Profit | 122.20M | 65.30M | 377.56M | -108.75M | 244.19M | -57.64M |
| EBITDA | -5.21M | -34.24M | -143.21M | -82.73M | -151.62M | -328.46M |
| Net Income | -140.94M | -169.33M | -269.39M | -197.28M | -246.92M | -445.27M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 1.63B | 1.69B | 1.78B | 1.75B | 1.90B |
| Cash, Cash Equivalents and Short-Term Investments | 1.29M | 1.29M | 3.38M | 1.37M | 858.00K | 1.01M |
| Total Debt | 0.00 | 2.25B | 2.12B | 2.39B | 1.83B | 1.88B |
| Total Liabilities | 1.63B | 3.26B | 3.15B | 2.97B | 2.74B | 2.65B |
| Stockholders Equity | -1.63B | -1.63B | -1.46B | -1.19B | -994.62M | -750.93M |
Cash Flow | ||||||
| Free Cash Flow | -37.27M | -121.78M | -114.54M | -70.50M | -355.84M | -407.36M |
| Operating Cash Flow | -16.76M | -90.06M | -78.91M | 23.65M | -247.13M | -172.16M |
| Investing Cash Flow | -21.83M | -36.36M | -49.70M | -78.17M | -126.45M | -229.00M |
| Financing Cash Flow | 38.44M | 126.30M | 128.65M | 55.64M | 373.43M | 395.06M |
Krebs Biochemicals & Industries Ltd. Technical Analysis
Neutral
71.00
Price Trends
55.34
Positive
58.31
Negative
59.25
Negative
Market Momentum
0.42
Negative
52.39
Neutral
25.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KREBSBIO, the sentiment is Neutral. The current price of 71 is above the 20-day moving average (MA) of 55.85, above the 50-day MA of 55.34, and above the 200-day MA of 59.25, indicating a neutral trend. The MACD of 0.42 indicates Negative momentum. The RSI at 52.39 is Neutral, neither overbought nor oversold. The STOCH value of 25.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:KREBSBIO.
Krebs Biochemicals & Industries Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ₹1.68B | 11.60 | ― | 0.70% | 4.29% | 2.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹1.26B | 35.92 | ― | ― | 0.46% | -83.31% | |
49 Neutral | ₹1.60B | 22.17 | ― | 1.19% | 13.51% | -14.80% | |
47 Neutral | ₹1.23B | -8.65 | ― | ― | -29.72% | 47.98% | |
47 Neutral | ₹534.76M | 111.02 | ― | ― | 9.31% | -82.71% | |
45 Neutral | ₹475.10M | -0.26 | ― | 0.67% | -39.80% | -452.04% |
* General Sector Average
IN:KREBSBIO
Krebs Biochemicals & Industries Ltd.
57.16
-23.84
-29.43%
IN:ALPA
Alpa Laboratories Limited
60.05
-33.90
-36.08%
IN:BALPHARMA
Bal Pharma Limited
100.27
15.56
18.37%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
32.86
-9.86
-23.08%
IN:PAR
Par Drugs and Chemicals Limited
136.60
24.18
21.51%
IN:VIVIMEDLAB
Vivimed Labs Limited
5.73
0.83
16.94%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.